Published in AIDS on September 12, 2008
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother (2010) 1.53
HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One (2009) 1.42
Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol (2009) 1.30
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology (2010) 1.26
Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease--indication of an evolving epidemic in West Africa. Retrovirology (2010) 1.25
Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PLoS One (2012) 1.21
Genotypic prediction of HIV-1 subtype D tropism. Retrovirology (2011) 1.16
Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody. Structure (2010) 1.15
Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism. Antimicrob Agents Chemother (2014) 1.08
Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob Agents Chemother (2011) 1.07
HIV-1 coreceptor usage prediction without multiple alignments: an application of string kernels. Retrovirology (2008) 1.05
Tropism testing in the clinical management of HIV-1 infection. Curr Opin HIV AIDS (2009) 1.03
Characterization of partial and near full-length genomes of HIV-1 strains sampled from recently infected individuals in São Paulo, Brazil. PLoS One (2011) 1.02
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing. PLoS One (2013) 1.00
TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches. J Clin Microbiol (2010) 0.99
Genotypic prediction of HIV-1 CRF01-AE tropism. J Clin Microbiol (2012) 0.97
CoRSeqV3-C: a novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithm. Retrovirology (2013) 0.94
Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors. Antimicrob Agents Chemother (2011) 0.92
Analysis of infectious virus clones from two HIV-1 superinfection cases suggests that the primary strains have lower fitness. Retrovirology (2010) 0.91
HIV-1 tropism determination using a phenotypic Env recombinant viral assay highlights overestimation of CXCR4-usage by genotypic prediction algorithms for CRF01_AE and CRF02_AG [corrected]. PLoS One (2013) 0.89
Genetic characteristics, coreceptor usage potential and evolution of Nigerian HIV-1 subtype G and CRF02_AG isolates. PLoS One (2011) 0.88
Performance of genotypic algorithms for predicting HIV-1 tropism measured against the enhanced-sensitivity Trofile coreceptor tropism assay. J Clin Microbiol (2010) 0.87
Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection. J Clin Microbiol (2010) 0.86
Variability of HIV-1 genomes among children and adolescents from São Paulo, Brazil. PLoS One (2013) 0.85
High prevalence of CXCR4 usage among treatment-naive CRF01_AE and CRF51_01B-infected HIV-1 subjects in Singapore. BMC Infect Dis (2013) 0.84
Determination of the high prevalence of Dual/Mixed- or X4-tropism among HIV type 1 CRF01_AE in Hong Kong by genotyping and phenotyping methods. AIDS Res Hum Retroviruses (2013) 0.83
APOBEC3G/F as one possible driving force for co-receptor switch of the human immunodeficiency virus-1. Med Microbiol Immunol (2011) 0.83
HIV-1 tropism evolution after short-term maraviroc monotherapy in HIV-1-infected patients. Antimicrob Agents Chemother (2012) 0.83
Bioinformatic analysis of HIV-1 entry and pathogenesis. Curr HIV Res (2014) 0.83
Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism. J Clin Microbiol (2013) 0.83
Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy. J Antimicrob Chemother (2012) 0.83
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. Infection (2013) 0.79
Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients. J Antimicrob Chemother (2015) 0.78
RECall for automated genotypic tropism testing. J Clin Microbiol (2013) 0.78
Longitudinal Analysis of Cerebrospinal Fluid and Plasma HIV-1 Envelope Sequences Isolated From a Single Donor with HIV Asymptomatic Neurocognitive Impairment. J Virol Antivir Res (2015) 0.78
Frequency of coreceptor tropism in PBMC samples from HIV-1 recently infected blood donors by massively parallel sequencing: the REDS II study. Virol J (2015) 0.78
Switching of inferred tropism caused by HIV during interruption of antiretroviral therapy. J Clin Microbiol (2010) 0.78
Position-specific automated processing of V3 env ultra-deep pyrosequencing data for predicting HIV-1 tropism. Sci Rep (2015) 0.77
Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients. HIV AIDS (Auckl) (2010) 0.77
X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI. PLoS One (2011) 0.77
Comparative analysis of cell culture and prediction algorithms for phenotyping of genetically diverse HIV-1 strains from Cameroon. AIDS Res Ther (2009) 0.77
Genotypic prediction of tropism of highly diverse HIV-1 strains from Cameroon. PLoS One (2014) 0.76
HIV-1 coreceptor switch during 2 years of structured treatment interruptions. Eur J Clin Microbiol Infect Dis (2013) 0.76
Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc. HIV AIDS (Auckl) (2010) 0.76
HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc. PLoS One (2015) 0.76
Polymorphisms in the α4 integrin of neotropical primates: insights for binding of natural ligands and HIV-1 gp120 to the human α4β7. PLoS One (2011) 0.76
HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients. PLoS One (2012) 0.75
Determination of viral tropism by genotyping and phenotyping assays in Brazilian HIV-1-infected patients. Rev Inst Med Trop Sao Paulo (2014) 0.75
Performance comparison of next-generation sequencing platforms for determining HIV-1 coreceptor use. Sci Rep (2017) 0.75
Envelope gene evolution and HIV-1 neuropathogenesis. J Neuroinfect Dis (2015) 0.75
HIV gp120 sequence variability associated with HAND in Hispanic Women. J Virol Antivir Res (2015) 0.75
The Pace of Co-receptor Tropism Switch in HIV-1 Infected Individuals after Recent Infection. J Virol (2017) 0.75
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet (2006) 10.91
Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med (2008) 6.60
Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med (2014) 4.70
Hepatitis E. Lancet (2012) 4.43
Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog (2008) 3.02
Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis (2011) 2.75
A systematic review of computer-based patient record systems and quality of care: more randomized clinical trials or a broader approach? Int J Qual Health Care (2004) 2.31
Hepatitis E virus infection. Clin Microbiol Rev (2014) 2.21
Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology (2011) 2.01
Hepatitis E virus genotype 3 diversity, France. Emerg Infect Dis (2009) 1.99
Hepatitis E in the south west of France in individuals who have never visited an endemic area. J Med Virol (2004) 1.85
High prevalence of anti-hepatitis E virus antibodies in blood donors from South West France. J Med Virol (2008) 1.84
Correlates of late HIV diagnosis: implications for testing policy. Int J STD AIDS (2007) 1.78
Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis (2010) 1.75
Hepatitis E virus and neurologic disorders. Emerg Infect Dis (2011) 1.70
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr (2005) 1.63
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother (2010) 1.53
An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients. Transplantation (2015) 1.52
Does chronic hepatitis E virus infection exist in immunocompetent patients? Hepatology (2014) 1.49
Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest (2011) 1.49
Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant (2010) 1.48
Hepatitis E is an autochthonous disease in industrialized countries. Analysis of 23 patients in South-West France over a 13-month period and comparison with hepatitis A. Gastroenterol Clin Biol (2006) 1.47
Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS (2009) 1.46
Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study. J Clin Microbiol (2005) 1.45
Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology (2010) 1.44
Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation (2010) 1.44
HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One (2009) 1.42
Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol (2007) 1.39
Occult hepatitis C virus infection in hemodialysis patients: examining the evidence. Am J Kidney Dis (2009) 1.39
R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2005) 1.37
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology (2002) 1.36
Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr (2007) 1.35
High-Risk groups for late diagnosis of HIV infection: a need for rethinking testing policy in the general population. AIDS Patient Care STDS (2006) 1.34
New natural intergenotypic (2/5) recombinant of hepatitis C virus. J Virol (2007) 1.34
CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS (2010) 1.32
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother (2005) 1.30
Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol (2009) 1.30
A large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Med (2009) 1.29
FOXP3 mRNA levels are decreased in peripheral blood CD4+ lymphocytes from HIV-positive patients. J Acquir Immune Defic Syndr (2005) 1.27
Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl (2010) 1.26
Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS (2003) 1.24
Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. J Acquir Immune Defic Syndr (2010) 1.24
Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J Clin Virol (2009) 1.24
Deciphering the molecular basis of wine yeast fermentation traits using a combined genetic and genomic approach. G3 (Bethesda) (2011) 1.23
Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes. AIDS (2004) 1.22
Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol (2006) 1.22
Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol (2011) 1.21
Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J Infect Dis (2002) 1.20
TaqMan amplification system with an internal positive control for HCV RNA quantitation. J Clin Virol (2004) 1.19
Persistence of distinct HIV-1 populations in blood monocytes and naive and memory CD4 T cells during prolonged suppressive HAART. AIDS (2005) 1.19